RHHBY - Meet members of the 2021 IPO class: Biotechs - 1

A list of 62 recent IPOs have just entered The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations. Simultaneously, the new entrants will be part of the Russell 3000 index, which represents Wall Street’s 3,000 largest stocks. As part of our series on the recently-IPOd healthcare stocks joining the group, in this article, we discuss four biotech stocks making their debut in The Russell 2000. Adagio Therapeutics  A clinical-stage biotech company focused on infectious diseases, Adagio Therapeutics (NASDAQ:ADGI) has more than doubled in value since its public debut in early August. Adagio (ADGI) sought ~$309 million in gross proceeds from its public offering partly to fund the development of its lead candidate ADG20, which is undergoing pivotal trials for both treatment and prevention of COVID-19. While Adagio (ADGI) with its experimental COVID-19 antibody joins a crowded space dominated by established players such as Regeneron (NASDAQ:REGN)/Roche (OTCQX:RHHBY), Eli Lilly (NYSE:LLY), and Vir Biotechnology

For further details see:

Meet members of the 2021 IPO class: Biotechs - 1